Literature DB >> 21368173

A neurodegenerative disease mutation that accelerates the clearance of apoptotic cells.

Aimee W Kao1, Robin J Eisenhut, Lauren Herl Martens, Ayumi Nakamura, Anne Huang, Josh A Bagley, Ping Zhou, Alberto de Luis, Lukas J Neukomm, Juan Cabello, Robert V Farese, Cynthia Kenyon.   

Abstract

Frontotemporal lobar degeneration is a progressive neurodegenerative syndrome that is the second most common cause of early-onset dementia. Mutations in the progranulin gene are a major cause of familial frontotemporal lobar degeneration [Baker M, et al. (2006) Nature 442:916-919 and Cruts M, et al. (2006) Nature 442:920-924]. Although progranulin is involved in wound healing, inflammation, and tumor growth, its role in the nervous system and the mechanism by which insufficient levels result in neurodegeneration are poorly understood [Eriksen and Mackenzie (2008) J Neurochem 104:287-297]. We have characterized the normal function of progranulin in the nematode Caenorhabditis elegans. We found that mutants lacking pgrn-1 appear grossly normal, but exhibit fewer apoptotic cell corpses during development. This reduction in corpse number is not caused by reduced apoptosis, but instead by more rapid clearance of dying cells. Likewise, we found that macrophages cultured from progranulin KO mice displayed enhanced rates of apoptotic-cell phagocytosis. Although most neurodegenerative diseases are thought to be caused by the toxic effects of aggregated proteins, our findings suggest that susceptibility to neurodegeneration may be increased by a change in the kinetics of programmed cell death. We propose that cells that might otherwise recover from damage or injury are destroyed in progranulin mutants, which in turn facilitates disease progression.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21368173      PMCID: PMC3060230          DOI: 10.1073/pnas.1100650108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  50 in total

1.  Quantitative analysis of pathways controlling extrinsic apoptosis in single cells.

Authors:  John G Albeck; John M Burke; Bree B Aldridge; Mingsheng Zhang; Douglas A Lauffenburger; Peter K Sorger
Journal:  Mol Cell       Date:  2008-04-11       Impact factor: 17.970

2.  Genetic variability in progranulin contributes to risk for clinically diagnosed Alzheimer disease.

Authors:  N Brouwers; K Sleegers; S Engelborghs; S Maurer-Stroh; I Gijselinck; J van der Zee; B A Pickut; M Van den Broeck; M Mattheijssens; K Peeters; J Schymkowitz; F Rousseau; J-J Martin; M Cruts; P P De Deyn; C Van Broeckhoven
Journal:  Neurology       Date:  2008-06-18       Impact factor: 9.910

Review 3.  Progranulin: normal function and role in neurodegeneration.

Authors:  Jason L Eriksen; Ian R A Mackenzie
Journal:  J Neurochem       Date:  2007-10-22       Impact factor: 5.372

4.  Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration.

Authors:  R Ghidoni; L Benussi; M Glionna; M Franzoni; G Binetti
Journal:  Neurology       Date:  2008-09-03       Impact factor: 9.910

5.  Progranulin (PGRN) expression in ALS: an immunohistochemical study.

Authors:  D Irwin; C F Lippa; A Rosso
Journal:  J Neurol Sci       Date:  2008-10-11       Impact factor: 3.181

6.  Progranulin genetic variability contributes to amyotrophic lateral sclerosis.

Authors:  K Sleegers; N Brouwers; S Maurer-Stroh; M A van Es; P Van Damme; P W J van Vught; J van der Zee; S Serneels; T De Pooter; M Van den Broeck; M Cruts; J Schymkowitz; P De Jonghe; F Rousseau; L H van den Berg; W Robberecht; C Van Broeckhoven
Journal:  Neurology       Date:  2008-01-09       Impact factor: 9.910

7.  Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis.

Authors:  T J Kwiatkowski; D A Bosco; A L Leclerc; E Tamrazian; C R Vanderburg; C Russ; A Davis; J Gilchrist; E J Kasarskis; T Munsat; P Valdmanis; G A Rouleau; B A Hosler; P Cortelli; P J de Jong; Y Yoshinaga; J L Haines; M A Pericak-Vance; J Yan; N Ticozzi; T Siddique; D McKenna-Yasek; P C Sapp; H R Horvitz; J E Landers; R H Brown
Journal:  Science       Date:  2009-02-27       Impact factor: 47.728

8.  Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members.

Authors:  NiCole Finch; Matt Baker; Richard Crook; Katie Swanson; Karen Kuntz; Rebecca Surtees; Gina Bisceglio; Anne Rovelet-Lecrux; Bradley Boeve; Ronald C Petersen; Dennis W Dickson; Steven G Younkin; Vincent Deramecourt; Julia Crook; Neill R Graff-Radford; Rosa Rademakers
Journal:  Brain       Date:  2009-01-21       Impact factor: 13.501

9.  Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival.

Authors:  Philip Van Damme; Annelies Van Hoecke; Diether Lambrechts; Peter Vanacker; Elke Bogaert; John van Swieten; Peter Carmeliet; Ludo Van Den Bosch; Wim Robberecht
Journal:  J Cell Biol       Date:  2008-03-31       Impact factor: 10.539

10.  Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6.

Authors:  Caroline Vance; Boris Rogelj; Tibor Hortobágyi; Kurt J De Vos; Agnes Lumi Nishimura; Jemeen Sreedharan; Xun Hu; Bradley Smith; Deborah Ruddy; Paul Wright; Jeban Ganesalingam; Kelly L Williams; Vineeta Tripathi; Safa Al-Saraj; Ammar Al-Chalabi; P Nigel Leigh; Ian P Blair; Garth Nicholson; Jackie de Belleroche; Jean-Marc Gallo; Christopher C Miller; Christopher E Shaw
Journal:  Science       Date:  2009-02-27       Impact factor: 47.728

View more
  64 in total

1.  Functional genomic analyses identify pathways dysregulated by progranulin deficiency, implicating Wnt signaling.

Authors:  Ezra Y Rosen; Eric M Wexler; Revital Versano; Giovanni Coppola; Fuying Gao; Kellen D Winden; Michael C Oldham; Lauren Herl Martens; Ping Zhou; Robert V Farese; Daniel H Geschwind
Journal:  Neuron       Date:  2011-09-21       Impact factor: 17.173

Review 2.  Potential roles of microglial cell progranulin in HIV-associated CNS pathologies and neurocognitive impairment.

Authors:  Hyeon-Sook Suh; Benjamin B Gelman; Sunhee C Lee
Journal:  J Neuroimmune Pharmacol       Date:  2014-03       Impact factor: 4.147

3.  Progranulin in the hematopoietic compartment protects mice from atherosclerosis.

Authors:  Andrew D Nguyen; Thi A Nguyen; Rajesh K Singh; Delphine Eberlé; Jiasheng Zhang; Jess Porter Abate; Anatalia Robles; Suneil Koliwad; Eric J Huang; Frederick R Maxfield; Tobias C Walther; Robert V Farese
Journal:  Atherosclerosis       Date:  2018-08-30       Impact factor: 5.162

4.  Opposing effects of progranulin deficiency on amyloid and tau pathologies via microglial TYROBP network.

Authors:  Hideyuki Takahashi; Zoe A Klein; Sarah M Bhagat; Adam C Kaufman; Mikhail A Kostylev; Tsuneya Ikezu; Stephen M Strittmatter
Journal:  Acta Neuropathol       Date:  2017-01-09       Impact factor: 17.088

Review 5.  Cellular effects of progranulin in health and disease.

Authors:  Louis De Muynck; Philip Van Damme
Journal:  J Mol Neurosci       Date:  2011-05-25       Impact factor: 3.444

6.  Strikingly different clinicopathological phenotypes determined by progranulin-mutation dosage.

Authors:  Katherine R Smith; John Damiano; Silvana Franceschetti; Stirling Carpenter; Laura Canafoglia; Michela Morbin; Giacomina Rossi; Davide Pareyson; Sara E Mole; John F Staropoli; Katherine B Sims; Jada Lewis; Wen-Lang Lin; Dennis W Dickson; Hans-Henrik Dahl; Melanie Bahlo; Samuel F Berkovic
Journal:  Am J Hum Genet       Date:  2012-05-17       Impact factor: 11.025

Review 7.  Progranulin, lysosomal regulation and neurodegenerative disease.

Authors:  Aimee W Kao; Andrew McKay; Param Priya Singh; Anne Brunet; Eric J Huang
Journal:  Nat Rev Neurosci       Date:  2017-04-24       Impact factor: 34.870

Review 8.  RNA Binding Proteins and the Pathogenesis of Frontotemporal Lobar Degeneration.

Authors:  Jeffrey W Hofmann; William W Seeley; Eric J Huang
Journal:  Annu Rev Pathol       Date:  2018-10-24       Impact factor: 23.472

Review 9.  Frontotemporal degeneration, the next therapeutic frontier: molecules and animal models for frontotemporal degeneration drug development.

Authors:  Adam L Boxer; Michael Gold; Edward Huey; Fen-Biao Gao; Edward A Burton; Tiffany Chow; Aimee Kao; Blair R Leavitt; Bruce Lamb; Megan Grether; David Knopman; Nigel J Cairns; Ian R Mackenzie; Laura Mitic; Erik D Roberson; Daniel Van Kammen; Marc Cantillon; Kathleen Zahs; Stephen Salloway; John Morris; Gary Tong; Howard Feldman; Howard Fillit; Susan Dickinson; Zaven Khachaturian; Margaret Sutherland; Robert Farese; Bruce L Miller; Jeffrey Cummings
Journal:  Alzheimers Dement       Date:  2012-10-05       Impact factor: 21.566

Review 10.  Mouse models of frontotemporal dementia.

Authors:  Erik D Roberson
Journal:  Ann Neurol       Date:  2012-12       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.